Symbols

ASRT

Assertio Holdings·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 5

Bearish signal 0

Ample Liquidity

High Gross Profit Margin

Significant Net Income Growth

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ASRT

Assertio Holdings, Inc.

A specialty pharmaceutical company that develops prescription drugs focused on pain and central nervus system conditions and diseases

Industry

Pharmaceutical

Established Date

Listing Date

12/17/2003

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.assertiotx.com

Security Type

Common stock

Office address

100 South Saunders Road, Suite 300, Lake Forest, Illinois 60045

Business

Introduction

Assertio Holdings, Inc., is a leading diversified, commercial pharmaceutical company focused on providing unique products that enhance treatment options for patients in need. On May 19, 2020, Assertio implemented the Assertio Reorganization pursuant to the Merger Agreement and Plan. Assertio Therapeutics is a wholly-owned subsidiary of Assertio Holdings.

Earnings Call

Q1/2025

Estimate EPS0

Actual EPS-0.14

Estimate Revenue27.52M

Actual Revenue26.49M

Assertio's Q1 2025: Unraveling Contradictions in Strategy, Litigation Impact, and Rolvedon's Future

May 20,2025 07:36·
Earnings Decrypt

Q2/2025

Estimate EPS-0.01

Actual EPS0.02

Estimate Revenue27.97M

Actual Revenue28.80M

Assertio Holdings Q2 2025: Examining Contradictions in Rolvedon and Sympazan Sales Dynamics

Aug 11,2025 07:56·
Earnings Decrypt

Company Financials

EPS

ASRT has released its 2025 Q3 earnings. EPS was reported at 0.18, versus the expected 0, beating expectations. The chart below visualizes how ASRT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ASRT has released its 2025 Q3 earnings report, with revenue of 49.46M, reflecting a YoY change of 69.36%, and net profit of 11.45M, showing a YoY change of 491.82%. The Sankey diagram below clearly presents ASRT's revenue sources and cost distribution.